Fabrice André has been elected as the President of the ESMO for the term 2025-2026

As the Head of the Research Division at Gustave Roussy Cancer Campus in France, Professor André has dedicated his career to advancing cancer treatment through innovative research and clinical trials.

In his role as ESMO President, Professor André aims to drive the implementation of technological innovations in oncology, enhancing both patient care and the working conditions for oncologists. He emphasizes the importance of integrating digital technologies and biotechnologies into clinical practice to simplify treatment decisions and reduce patient burdens. His leadership is expected to strengthen ESMO’s position as a global leader in disseminating oncology knowledge and fostering collaboration among professionals in the field.

Professional Background

Fabrice André is a medical oncologist specializing in breast cancer. He currently serves as the Director of Research at Institute Gustave Roussy in Villejuif, France, and is a Professor of Medicine at the University of Paris-Saclay. In addition to his academic and clinical achievements, Dr. André is the President of the European Society for Medical Oncology (ESMO), a role that underscores his leadership in advancing global cancer care.

He served on the Annals of Oncology Editorial Board from 2010 to 2013, became an Associate Editor in 2014, and held the position of Editor-in-Chief from 2017 to 2023.

He was the first chair of the ESMO Young Oncologist Committee, and he has been involved with the ESMO Breast Cancer Faculty as its coordinator from 2012 to 2014. He has been a member since 2015. Additionally, Professor André was a member of the ESMO Cancer Research Faculty from 2012 to 2014, chaired the ESMO Translational Research and Precision Medicine Working Group until the end of 2019, and has been a member since 2020. He is also a part of the ESMO Council and served as the Scientific Co-Chair of both the ESMO 2022 Congress and the MAP Congress.

ESMO has played a pivotal role in shaping his career, providing him with opportunities for leadership and collaboration that have significantly contributed to his expertise and recognition in the field of oncology.

Research Focus

Professor Fabrice André’s research focuses on biomarkers and personalized therapies, with an emphasis on discovering biomarkers, developing targeted agents, and implementing personalized medicine. His team consists of 80 professionals specializing in basic sciences, bioinformatics, biotechnology, and clinical research. He leads Phase I-III clinical trials investigating targeted therapies for breast cancer and oversees large-scale national studies aimed at integrating high-throughput technologies into healthcare systems.

With over 300 peer-reviewed publications in prestigious journals such as Nature, The New England Journal of Medicine, The Lancet, and Nature Medicine, Professor André is a prominent figure in oncology. He chairs the biomarker group at UNICANCER (the French cooperative group) and has served on scientific committees for several international conferences, including SABCS, AACR, ECCO, ESMO, and IMPAKT.

“My main advice is that publication should not be the ultimate goal of research. The true aim is to advance the field and help patients, and this is the spark that produces the most impactful, high-quality research. Publishing is merely a tool for sharing knowledge and spreading your findings to a broader audience.”

Early Life and Career

Fabrice André, born on May 10, 1972, pursued his secondary education in Villard-de-Lans and higher studies in Grenoble. He earned his medical degree in oncology from the University of Grenoble in 2002 and completed a PhD in Biotechnology at the University of Paris in 2005, with a thesis titled “Cancer Immunotherapy.” Following this, he served as a Visiting Assistant Professor at the MD Anderson Cancer Center in Texas in 2006.

Dr. André completed his residency in Medical Oncology at Gustave Roussy, where he became a University Professor-Hospital Practitioner in the Department of Medical Oncology in 2012.

From 2010 to 2016, Dr. André directed the Inserm 981/Gustave Roussy/Université Paris-XI joint research unit, focusing on predictive biomarkers and novel molecular strategies in anticancer therapy. In 2010, he created his own research lab at Gustave Roussy. Since 2020, he has held the position of Research Director at Gustave Roussy, continuing his groundbreaking work in oncology.

Achievements and Awards

Professor Fabrice André has made significant contributions to the field of oncology, particularly in breast cancer research and personalized medicine. His achievements and awards reflect his leadership and pioneering work in cancer treatment. Here are some of the awards:

• Young Investigator Award – American Society of Clinical Oncology (ASCO) (2002)
• Career Development Award – American Society of Clinical Oncology (ASCO) (2006)
• ESMO Georges Mathé Cancer Research Prize (2011)
• Outstanding Investigator Award in Breast Cancer – American Association for Cancer Research (AACR) (2021)
• Brinker Award for Scientific Distinction in Clinical Research – Susan G. Komen Foundation (2024)
• Giants of Cancer Care Award – American Society of Clinical Oncology (ASCO) (2024)
• Top 100 Xfluencers in Breast Cancer – OncoDaily (2024)

Interviews with Fabrice André

Annals of Oncology 35th Anniversary – Interview with Prof. Fabrice André

MAP conference: an interview with Fabrice André

Fabrice André: “We need real political will to move from mass medicine to precision medicine” – ROSE-UP

France 2030 – Interview with Fabrice André

Professor Fabrice André on RlapsRisk BC⎢Owkin

Behind the Breakthroughs: The Future of Personalized Medicine with Fabrice André – BCRF, 2022